Abstract
Objective: Aim: to study of antihypertensive, antiremodelling efficacy and clinical tolerability of monotherapy with zofenopril in patients with mild to moderate arterial hypertension (AH). Design and method: The study included 30 patients with mild to moderate AH (I-II stage of AH, ESC/ESH 2013), in average age 49,93 ± 9,0 yrs. Blood pressure BP was measured by Korotkof method. Echocardiography performed according to Penn Convention Method, endothelium dependent vasodilatation (EDVD) of brachial artery was determined in reactive hyperemia test, intima-media thickness (IMT) of common carotid artery measured by ultrasound, blood lipid and glucose levels were determined using biochemical methods, all measurements performed before and after 12 weeks of treatment with zofenopril (Zocardis, Berlin-Chemi, Menarini Group). Results: During the 12 weekly monotherapy with zofenopril in daily dose 36.0 ± 19.54 mg there were significantly decrease of systolic and diastolic BP on 19.53 ± 5.93% and 18.64 ± 7.18% respectively, with achieved goal BP level in 83.3% cases. Cardioprotective efficacy of zofenopril expressed in significantly regress of left ventricular hypertrophy: left ventricular mass index reduce from 117.84 ± 32.5 m/g2 to 106.15 ± 28.6 m/g2, (p = 0.0001), with improvement and normalization EDVD of brachial artery: D% from 9.86 ± 3.82% to 14.13 ± 6.17% (p = 0.0001), and significantly decrease of IMT: from 1.0 ± 0.3 mm to 0.91 ± 0.24 mm (p = 0.002). There were no significantly changes in blood lipid and glucose levels. Tolerability of zofenopril was good without any side effects. All patients finished 12-weekly therapy. Conclusions: During the monotherapy with zofenopril were shown significantly high antihypertensive, antiremodelling efficacy with metabolic neutrality and good clinical tolerability of drug in patients with mild to moderate AH.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call